25 April 2023 | News
As of the end of 2022, more than 20 gene therapy drugs have been approved and entered clinical applications globally
image credit- prnewswire
OBiO Technology (Shanghai) Corp., a leading gene and cell therapy contract development and manufacturing organisation (CDMO) in China, has announced the launching of a new GMP manufacturing base, named OBiO Intelli-M.
The new base is located in the China (Shanghai) Pilot Free Trade Zone, Lin-Gang Special Area, with 29 production lines and 828,000+ square feet in area, which is one of the biggest super factories for gene therapy in the world.
At the opening ceremony, OBiO showed the holistic process development capability and large-scale GMP manufacturing capacity in variety gene and cell therapies. According to OBiO's introduction, OBiO Intelli-M contains 11 different vector production lines from Cytiva, Sartorius, ThermoFisher, Austar, for different kind of gene vector manufacturing. These lines include manufacturing processes with cell factory, roller bottle, fixed-bed, and 50 L/200 L/250 L/500 L/1000 L/2000 L single-use bioreactor.
Meanwhile, OBiO Intelli-M have 18 cell production lines for autologous and allogeneic immune cell therapies and stem cell therapies, in which 3 complete independence lines are used for cell therapies in infectious disease patient.
OBiO has reached strategic cooperations in commercial manufacturing services with ImmVira, a leading biotech focused on development of new generation novel anti-cancer drugs, and CHINAGENE THCH, a leading AAV-based therapeutics developer. Moreover, OBiO and HOPE FOR RARE FOUNDATION have reached the agreement on comprehensively cooperation to promote the clinical transformation of advanced therapies.